Cardiome signs deal with Eddingpharm to market heart drug in China

24 August 2015

Canadian firm Cardiome Pharma (Nasdaq: CRME) on Monday said it has signed a deal with privately-held Eddingpharm to market its drug to treat heart conditions, in China, for an undisclosed sum.

The company in a statement said the payments to the China-based Eddingpharm will include milestone payments and minimum annual commercial commitments.

Xin Ni, Eddingpharrm's chief executive, said: "The addition of Aggrastat (tirofiban hydrochloride) to our hospital product line reaffirms our commitment to bringing high quality products to our customers, while at the same time, is a stepping stone to building a leading cardiovascular franchise that also includes Brinavess."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK